# Moderna, Inc.: financial statements, quarterly

MRNA · Nasdaq · CIK 1682852 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mrna.md) · [Financials](/companies/mrna/financials.md) · [Filings](/companies/mrna/filings.md) · [Insiders](/companies/mrna/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mrna/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,831](/filings/0001682852-24-000060.md) | [2,811 d](/filings/0001682852-26-000033.md) | [167](/filings/0001682852-25-000034.md) | [241](/filings/0001682852-25-000044.md) | [1,862](/filings/0001682852-25-000075.md) | [966 d](/filings/0001682852-26-000033.md) | [108](/filings/0001682852-26-000060.md) | [142](/filings/0001682852-26-000150.md) | [1,016](/filings/0001682852-25-000075.md) | [678 d](/filings/0001682852-26-000033.md) | [389](/filings/0001682852-26-000060.md) | [145](/filings/0001682852-26-000150.md) |
| Cost of revenue | $m | [2,241](/filings/0001682852-24-000060.md) | [929 d](/filings/0001682852-26-000033.md) | [96.0](/filings/0001682852-25-000034.md) | [115](/filings/0001682852-25-000044.md) | [514](/filings/0001682852-25-000075.md) | [739 d](/filings/0001682852-26-000033.md) | [90.0](/filings/0001682852-26-000060.md) | [119](/filings/0001682852-26-000150.md) | [207](/filings/0001682852-25-000075.md) | [452 d](/filings/0001682852-26-000033.md) | [955](/filings/0001682852-26-000060.md) | [93.0](/filings/0001682852-26-000150.md) |
| Research and development | $m | [1,160](/filings/0001682852-24-000060.md) | [1,406 d](/filings/0001682852-26-000033.md) | [1,063](/filings/0001682852-25-000034.md) | [1,221](/filings/0001682852-25-000044.md) | [1,137](/filings/0001682852-25-000075.md) | [1,122 d](/filings/0001682852-26-000033.md) | [856](/filings/0001682852-26-000060.md) | [700](/filings/0001682852-26-000150.md) | [801](/filings/0001682852-25-000075.md) | [775 d](/filings/0001682852-26-000033.md) | [649](/filings/0001682852-26-000060.md) | [651](/filings/0001682852-26-000150.md) |
| Operating income | $m | [(2,012)](/filings/0001682852-24-000060.md) | [6.0 d](/filings/0001682852-26-000033.md) | [(1,266)](/filings/0001682852-25-000034.md) | [(1,363)](/filings/0001682852-25-000044.md) | [(70.0)](/filings/0001682852-25-000075.md) | [(1,246) d](/filings/0001682852-26-000033.md) | [(1,050)](/filings/0001682852-26-000060.md) | [(907)](/filings/0001682852-26-000150.md) | [(260)](/filings/0001682852-25-000075.md) | [(857) d](/filings/0001682852-26-000033.md) | [(1,388)](/filings/0001682852-26-000060.md) | [(815)](/filings/0001682852-26-000150.md) |
| Income tax | $m | [1,672](/filings/0001682852-24-000060.md) | [(147) d](/filings/0001682852-26-000033.md) | [10.0](/filings/0001682852-25-000034.md) | [0.0](/filings/0001682852-25-000044.md) | [8.0](/filings/0001682852-25-000075.md) | [(64.0) d](/filings/0001682852-26-000033.md) | [7.0](/filings/0001682852-26-000060.md) | [7.0](/filings/0001682852-26-000150.md) | [13.0](/filings/0001682852-25-000075.md) | [27.0 d](/filings/0001682852-26-000033.md) | [9.0](/filings/0001682852-26-000060.md) | [15.0](/filings/0001682852-26-000150.md) |
| Net income | $m | [(3,630)](/filings/0001682852-24-000060.md) | [217 d](/filings/0001682852-26-000033.md) | [(1,175)](/filings/0001682852-25-000034.md) | [(1,279)](/filings/0001682852-25-000044.md) | [13.0](/filings/0001682852-25-000075.md) | [(1,120) d](/filings/0001682852-26-000033.md) | [(971)](/filings/0001682852-26-000060.md) | [(825)](/filings/0001682852-26-000150.md) | [(200)](/filings/0001682852-25-000075.md) | [(826) d](/filings/0001682852-26-000033.md) | [(1,343)](/filings/0001682852-26-000060.md) | [(782)](/filings/0001682852-26-000150.md) |
| Diluted EPS | $ per share | [(9.53)](/filings/0001682852-24-000060.md) | not reported | [(3.07)](/filings/0001682852-25-000034.md) | [(3.33)](/filings/0001682852-25-000044.md) | [0.03](/filings/0001682852-25-000075.md) | not reported | [(2.52)](/filings/0001682852-26-000060.md) | [(2.13)](/filings/0001682852-26-000150.md) | [(0.51)](/filings/0001682852-25-000075.md) | not reported | [(3.40)](/filings/0001682852-26-000060.md) | [(1.97)](/filings/0001682852-26-000150.md) |
| Basic EPS | $ per share | [(9.53)](/filings/0001682852-24-000060.md) | not reported | [(3.07)](/filings/0001682852-25-000034.md) | [(3.33)](/filings/0001682852-25-000044.md) | [0.03](/filings/0001682852-25-000075.md) | not reported | [(2.52)](/filings/0001682852-26-000060.md) | [(2.13)](/filings/0001682852-26-000150.md) | [(0.51)](/filings/0001682852-25-000075.md) | not reported | [(3.40)](/filings/0001682852-26-000060.md) | [(1.97)](/filings/0001682852-26-000150.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [2.9](/filings/0001682852-24-000060.md) | [2.9](/filings/0001682852-26-000033.md) | [2.1](/filings/0001682852-25-000034.md) | [2.5](/filings/0001682852-25-000044.md) | [1.6](/filings/0001682852-25-000075.md) | [1.9](/filings/0001682852-26-000033.md) | [1.6](/filings/0001682852-26-000060.md) | [1.3](/filings/0001682852-26-000150.md) | [1.1](/filings/0001682852-25-000075.md) | [2.6](/filings/0001682852-26-000150.md) | [1.9](/filings/0001682852-26-000060.md) | [1.7](/filings/0001682852-26-000150.md) |
| Current assets | $bn | [10.8](/filings/0001682852-23-000042.md) | [10.3](/filings/0001682852-25-000022.md) | [9.6](/filings/0001682852-24-000027.md) | [9.7](/filings/0001682852-24-000046.md) | [9.7](/filings/0001682852-24-000060.md) | [8.1](/filings/0001682852-26-000033.md) | [6.8](/filings/0001682852-25-000034.md) | [6.2](/filings/0001682852-25-000044.md) | [6.6](/filings/0001682852-25-000075.md) | [6.5](/filings/0001682852-26-000150.md) | [5.8](/filings/0001682852-26-000060.md) | [5.8](/filings/0001682852-26-000150.md) |
| Total assets | $bn | [19.5](/filings/0001682852-23-000042.md) | [18.4](/filings/0001682852-25-000022.md) | [16.7](/filings/0001682852-24-000027.md) | [15.7](/filings/0001682852-24-000046.md) | [15.8](/filings/0001682852-24-000060.md) | [14.1](/filings/0001682852-26-000033.md) | [12.7](/filings/0001682852-25-000034.md) | [12.0](/filings/0001682852-25-000044.md) | [12.1](/filings/0001682852-25-000075.md) | [12.3](/filings/0001682852-26-000150.md) | [11.5](/filings/0001682852-26-000060.md) | [11.0](/filings/0001682852-26-000150.md) |
| Current liabilities | $bn | [4.4](/filings/0001682852-23-000042.md) | [3.0](/filings/0001682852-25-000022.md) | [2.4](/filings/0001682852-24-000027.md) | [2.4](/filings/0001682852-24-000046.md) | [2.2](/filings/0001682852-24-000060.md) | [2.2](/filings/0001682852-26-000033.md) | [1.6](/filings/0001682852-25-000034.md) | [1.6](/filings/0001682852-25-000044.md) | [1.7](/filings/0001682852-25-000075.md) | [2.0](/filings/0001682852-26-000150.md) | [2.4](/filings/0001682852-26-000060.md) | [2.5](/filings/0001682852-26-000150.md) |
| Total liabilities | $bn | [6.0](/filings/0001682852-23-000042.md) | [4.6](/filings/0001682852-25-000022.md) | [3.9](/filings/0001682852-24-000027.md) | [4.0](/filings/0001682852-24-000046.md) | [3.9](/filings/0001682852-24-000060.md) | [3.2](/filings/0001682852-26-000033.md) | [2.6](/filings/0001682852-25-000034.md) | [2.6](/filings/0001682852-25-000044.md) | [2.8](/filings/0001682852-25-000075.md) | [3.7](/filings/0001682852-26-000150.md) | [4.1](/filings/0001682852-26-000060.md) | [4.2](/filings/0001682852-26-000150.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001682852-26-000033.md) | not reported | not reported | not reported | [0.6](/filings/0001682852-26-000150.md) | [0.6](/filings/0001682852-26-000060.md) | [0.6](/filings/0001682852-26-000150.md) |
| Shareholders' equity | $bn | [13.5](/filings/0001682852-24-000060.md) | [13.9](/filings/0001682852-26-000033.md) | [12.8](/filings/0001682852-25-000044.md) | [11.7](/filings/0001682852-25-000075.md) | [11.9](/filings/0001682852-25-000075.md) | [10.9](/filings/0001682852-26-000150.md) | [10.1](/filings/0001682852-26-000150.md) | [9.4](/filings/0001682852-26-000150.md) | [9.3](/filings/0001682852-25-000075.md) | [8.7](/filings/0001682852-26-000150.md) | [7.4](/filings/0001682852-26-000150.md) | [6.8](/filings/0001682852-26-000150.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1,600) d](/filings/0001682852-24-000060.md) | [622 d](/filings/0001682852-26-000033.md) | [(989)](/filings/0001682852-25-000034.md) | [(1,274) d](/filings/0001682852-25-000044.md) | [(1,566) d](/filings/0001682852-25-000075.md) | [825 d](/filings/0001682852-26-000033.md) | [(1,037)](/filings/0001682852-26-000060.md) | [(919) d](/filings/0001682852-26-000150.md) | [(847) d](/filings/0001682852-25-000075.md) | [930 d](/filings/0001682852-26-000033.md) | [(630)](/filings/0001682852-26-000060.md) | [(526) d](/filings/0001682852-26-000150.md) |
| Capital expenditure | $m | [140 d](/filings/0001682852-24-000060.md) | [220 d](/filings/0001682852-26-000033.md) | [196](/filings/0001682852-25-000034.md) | [182 d](/filings/0001682852-25-000044.md) | [151 d](/filings/0001682852-25-000075.md) | [522 d](/filings/0001682852-26-000033.md) | [117](/filings/0001682852-26-000060.md) | [3.0 d](/filings/0001682852-26-000150.md) | [33.0 d](/filings/0001682852-25-000075.md) | [39.0 d](/filings/0001682852-26-000033.md) | [62.0](/filings/0001682852-26-000060.md) | [37.0 d](/filings/0001682852-26-000150.md) |
| Share repurchases | $m | [(1.0) d](/filings/0001682852-24-000060.md) | [0.0 d](/filings/0001682852-26-000033.md) | [0.0](/filings/0001682852-24-000027.md) | [0.0 d](/filings/0001682852-24-000046.md) | [0.0 d](/filings/0001682852-24-000060.md) | [0.0 d](/filings/0001682852-26-000033.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [412](/filings/0001682852-23-000042.md) | [405](/filings/0001682852-24-000027.md) | [381](/filings/0001682852-24-000046.md) | [381](/filings/0001682852-24-000060.md) | [382](/filings/0001682852-25-000034.md) | [384](/filings/0001682852-25-000044.md) | [399](/filings/0001682852-25-000075.md) | [386](/filings/0001682852-26-000060.md) | [388](/filings/0001682852-26-000150.md) | [390](/filings/0001682852-25-000075.md) | [395](/filings/0001682852-26-000060.md) | [398](/filings/0001682852-26-000150.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 399,235,889 at 2026-07-24, from the cover of the [10-Q filed 2026-07-31](/filings/0001682852-26-000150.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.